Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014, according to a January 27 news release which also indicated portfolio transformation will focus the company on leading business.
Net sales and operating income both increased by 1% in 2014 to USD 58 billion and USD 10.7 billion respectively. Net income grew by 12% to USD 10.3 billion.
Growth products and Emerging Growth Markets continued to drive performance in 2014 Q4 with an increase of 14% to USD 4.7 billion, or 32% of Group net sales. Novartis also saw continued progress in transforming portfolio and increasing productivity with its divestment of Animal Health Division to Eli Lilly and Company, which completed on January 1, 2015.
No comments:
Post a Comment